Showing results (11-20 of 584) with videos related to
Sort By:
Pageof 59
The Journal of Clinical Endocrinology and Metabolism|November 5, 1997
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal womenF Labrie, P Diamond, L Cusan, et al.The Journal of Steroid Biochemistry and Molecular Biology|July 14, 2007
Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal womenF Labrie, A Bélanger, C Labrie, et al.International Journal of Cancer|February 1, 2000
Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude miceS Couillard, C Labrie, S Gauthier, et al.Urology|February 1, 1996
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigenF Labrie, B Candas, L Cusan, et al.Urology|January 14, 1998
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activityS Luo, C Martel, C Chen, et al.The Journal of Clinical Endocrinology and Metabolism|October 1, 1994
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old menA Bélanger, B Candas, A Dupont, et al.Urology|March 30, 1999
Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapyT H van der Kwast, B Têtu, B Candas, et al.Steroids|June 10, 1998
DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during agingF Labrie, A Bélanger, V Luu-The, et al.Endocrinology|May 16, 1998
Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouseC Martel, C Labrie, A Bélanger, et al.Cancer Surveys|January 1, 1995
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomyF Labrie, L Cusan, J L Gomez, et al.Pageof 59